Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

FDA Scrutinizes Infection Risk With Amgen Drug

By Drug Discovery Trends Editor | August 11, 2009

WASHINGTON (AP) – Federal health officials are questioning increased infection rates and tumors seen with an osteoporosis drug from Amgen that analysts say is key to the company’s growth.

The Food and Drug Administration said Tuesday that patients taking Amgen Inc.’s denosumab were more likely to develop infections of the skin, ear and urinary tract than patients taking placebo.

Amgen wants the FDA to approve denosumab as a treatment for postmenopausal osteoporosis and for the prevention of bone loss in patients being treated for breast and prostate cancer. About 10 million Americans have osteoporosis, which causes bones to thin and fracture, and nearly 45 million are at increased risk due to low bone density.

The drug is a genetically engineered version of a protein that helps block the breakdown of bone cells. But the FDA is concerned the drug, which also affects the immune system, can leave patients more vulnerable to infection.

On Thursday, the FDA will ask a panel of experts whether additional safety restrictions or studies are needed to make sure denosumab can be used safely. The agency is not required to follow the experts’ advice, though it usually does. The FDA is scheduled to make a decision on denosumab by October.

With millions of U.S. seniors at risk for bone fractures, denosumab represents a significant market opportunity for Amgen, with analysts predicting sales between $1 billion and $2 billion. Wall Street has pegged the company’s future growth to denosumab, as sales of its anemia drugs continue to slide on safety labeling restrictions.

Shares of Amgen rose $1.29, or 2.1 percent, to $62.53 in afternoon trading.

In documents posted online Tuesday, the FDA noted that 4.1 percent of patients taking Amgen’s drug reported infections, slightly higher than the 3.3 percent reported by patients taking placebo. Specifically, the FDA noted an increase in skin infections that required hospitalization.

“There is an increased risk of serious skin infections with denosumab that is important to the overall benefit risk assessment,” the FDA said in its review.

Amgen has proposed labeling to warn patients “to seek prompt medical attention if they develop signs or symptoms of cellulitis,” a serious type of skin infection.

Regulators also have concerns about higher rates of malignant tumors seen with denosumab. In data pulled from six studies of the drug conducted by Amgen, women taking denosumab were more likely to develop tumors of the breast, intestine and reproductive system.

If approved, denosumab would enter a $3.5 billion market of osteoporosis treatments, including GlaxoSmithKline PLC’s Boniva and Merck & Co. Inc.’s Fosamax.

While there are no head-to-head studies comparing denosumab to those drugs, medical experts say Amgen’s treatment could be easier for patients to use than older drugs. Whereas tablet drugs must be taken on a daily or weekly basis, denosumab is injected twice a year, reducing the chance that patients will stop taking their medication.

With eight other pills and injectable medicines on the market, including low-cost generic versions of Fosamax, denosumab’s success likely will hinge on its price. Amgen has not yet discussed pricing for denosumab, though its closest potential competitor, Novartis’ injectable drug Zometa, sells for about $1,300 per year.

A spokeswoman for Thousand Oaks, Calif.-based Amgen said the company will try to keep the drug affordable but declined to be more specific.

Denosumab also is under review in the European Union, Australia and Switzerland, where it would be marketed by British drugmaker GlaxoSmithKline.

Date: August 11, 2009
Source: Associated Press


Filed Under: Genomics/Proteomics

 

Related Articles Read More >

Spatial biology: Transforming our understanding of cellular environments
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
DNA helix 3D illustration. Mutations under microscope. Decoding genome. Virtual modeling of chemical processes. Hi-tech in medicine
Genomics in 2025: How $500 whole genome sequencing could democratize genomic data
A media release and Scientific Report image of Elizabeth Kellogg. - Camera Settings: ILCE-9M2, 12mm, ISO 1000, 1/80, f/3.2, Fri, 04-19-2024 at 10:10. v.12.01.23
St. Jude pioneers gene editing and structural biology to advance pediatric research
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE